Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Precision BioSciences Inc (DTIL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.87+21.55%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DTIL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve revenue growth | A primary condition in Precision BioSciences Inc's published investment case. The stated target is Revenue does not fall below $10 million in 2026. | Intact | Revenue falls below $10 million in 2026 | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue does not fall below $10 million in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
DTIL is a high-risk clinical-stage biotechnology company, where the long-term case depends on advancing treatments through clinical trials. The thesis is intact, though the recent signal has shifted from mildly favorable to mixed.
The valuation evidence describes DTIL as cheap versus peers, with a small expectations gap, but confidence in that assessment is low. The snapshot also says no fragility gates fired, so it does not point to a clear valuation strain.
Near term, recent performance is neutral, and an August earnings beat offers some support; however, DTIL remains loss-making and the next results carry a meaningful risk of a miss. Over the multi-year view, PBGENE-HBV has early clinical evidence, while the DMD trial is enrolling; cash fell from the first to the second quarter, and management expects existing cash, fiscal discipline, and an ATM facility to fund milestones through 2028.
The next HBV update, targeted for year-end 2026, and initial DMD safety data, also expected by year-end, will help show whether clinical progress continues. A guidance cut or weaker jobs data would add pressure, while continued strength from healthcare bellwethers could support the sector backdrop; the CEO transition and litigation are additional uncertainties.
For the next 1 to 3 years, the thesis rests on clinical progress and keeping enough cash to reach milestones, with high risk and volatile management limiting confidence. Recent performance has kept the core case intact, but the signal is mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Clinical data shows progress in hepatitis B treatment. |
| Improving |
| Clinical data fails to show elimination of cccDNA |
1-log (10-fold) cccDNA reduction vs elimination target PBGENE-HBV ELIMINATE-B study showed 1-log cccDNA reduction via liver biopsy data; next program update targeted for year-end 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Extend cash runway through 2028 | Precision BioSciences aims to extend cash through 2028. | Intact | Cash runway does not extend through 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.31 → $-2.74 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.31 | $14,400,000 | 3 / 4 |
| 2026-07-25 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-26 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-27 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-28 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-29 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-30 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-07-31 | $-2.31 | $14,400,000 | 3 / 4 |
| 2026-08-01 | $-2.31 | $14,400,000 | 3 / 4 |
| 2026-08-02 | $-1.89 | $12,520,000 | 3 / 5 |
| 2026-08-03 | $-2.31 | $14,400,000 | 3 / 4 |
| 2026-08-04 | $-2.48 | $14,400,000 | 3 / 4 |
| 2026-08-05 | $-2.48 | $14,400,000 | 3 / 4 |
| 2026-08-06 | $-2.18 | $7,660,000 | 3 / 5 |
| 2026-08-07 | $-2.48 | $9,540,000 | 3 / 3 |
| 2026-08-08 | $-2.18 | $7,660,000 | 3 / 5 |
| 2026-08-09 | $-2.18 | $7,660,000 | 3 / 5 |
| 2026-08-10 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-11 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-12 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-13 | $-2.14 | $7,660,000 | 3 / 5 |
| 2026-08-14 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-15 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-16 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-17 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-18 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-19 | $-2.58 | $9,540,000 | 3 / 3 |
| 2026-08-20 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-21 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-22 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-23 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-24 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-25 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-26 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-27 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-28 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-29 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-30 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-08-31 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-01 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-02 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-03 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-04 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-05 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-06 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-07 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-08 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-09 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-10 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-11 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-12 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-13 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-14 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-15 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-16 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-17 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-18 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-19 | $-2.64 | $9,300,000 | 3 / 3 |
| 2026-09-20 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-21 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-22 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-23 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-24 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-25 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-26 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-27 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-28 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-29 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-09-30 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-01 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-02 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-03 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-04 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-05 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-06 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-07 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-08 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-09 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-10 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-11 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-12 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-13 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-14 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-15 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-16 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-17 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-18 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-19 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-20 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-21 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-22 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-23 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-24 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-25 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-26 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-27 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-28 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-29 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-30 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-10-31 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-11-01 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-11-02 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-11-03 | $-2.84 | $8,875,000 | 3 / 3 |
| 2026-11-04 | $-2.74 | $8,175,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.